[Efficacy, effectiveness and safety of photodynamic therapy in age-related macular degeneration and pathologic myopia. Economic impact in the Community of Madrid]

Perez-Blanco V, Blasco JA, Sabes R
Record ID 32011001535
Authors' objectives:

To evaluate potential risks and benefits of the photodynamic therapy (PT) with verteporfin for treatment of age-related macular degeneration (AMD) and pathologic myopia (PM).
To estimate the economic impact that would have the health care system of the Community of Madrid (CM) using the treatment in susceptible patients.
Analyze the use of the PT in public hospitals of the CM.

Authors' recommendations: Evidence about effectiveness and efficiency of photodynamic therapy, and without alternative efficacious and safe treatments, use of therapy is recommended in patients :Initial moderate patient visual acuity, 20/40 o 6/12 according to the scale used.Evaluation of characteristics of occult subfoveal lesions.Use of therapy in the two hospital centers with enough experience is recommended in order to assure satisfactory results of treatment.However, more independent studies are necessary to provide the consistency of outcomes on effectiveness of previous studies. Clinical trials designed must include a longer time of follow-up.
Project Status: Completed
Year Published: 2004
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: Spain
MeSH Terms
  • Macular Degeneration
  • Myopia
  • Photochemotherapy
  • Spain
Organisation Name: Unidad de Evaluacion de Tecnologias Sanitarias
Contact Address: Elena Andradas Aragones, Unidad de Evaluacion de Tecnologias Sanitarias, Agencia Lain Entralgo, C/ Gran Via, 27, 8a, ES-28013 Madrid, Spain. Tel: +34 91 3089418; Fax: +34 91 3089458;
Contact Name: elena.andradas@salud.madrid.org
Contact Email: elena.andradas@salud.madrid.org
Copyright: <p>Unidad de Evaluacion de Tecnologias Sanitarias (UETS)</p>
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.